<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Mashelkar</title>
	<atom:link href="http://www.tapanray.in/tag/mashelkar/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Balancing IPR with Public Health Interest: Brickbats, Power Play and Bouquets</title>
		<link>http://www.tapanray.in/balancing-ipr-with-public-health-interest-brickbats-power-play-and-bouquets/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=balancing-ipr-with-public-health-interest-brickbats-power-play-and-bouquets</link>
		<comments>http://www.tapanray.in/balancing-ipr-with-public-health-interest-brickbats-power-play-and-bouquets/#comments</comments>
		<pubDate>Mon, 01 Jul 2013 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[Argentina]]></category>
		<category><![CDATA[Balancing]]></category>
		<category><![CDATA[blockbuster]]></category>
		<category><![CDATA[bouquets]]></category>
		<category><![CDATA[Brazil]]></category>
		<category><![CDATA[brickbats]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[Carlos]]></category>
		<category><![CDATA[Columbia]]></category>
		<category><![CDATA[Correa]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[debate]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[ever greening]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[good]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[inventive]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Judgment]]></category>
		<category><![CDATA[Leash]]></category>
		<category><![CDATA[Leashing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Mashelkar]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patentability]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[power play]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[raging]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reasonably]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Revised]]></category>
		<category><![CDATA[Section(3d)]]></category>
		<category><![CDATA[Section2(ja)]]></category>
		<category><![CDATA[South Africa]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USIBC]]></category>
		<category><![CDATA[wasteful]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[WOW]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2691</guid>
		<description><![CDATA[It is now a widely accepted dictum that Intellectual Property Rights (IPR), especially pharma patents, help fostering innovation and is critical in meeting unmet needs of the patients. However, the moot question still remains, what type pharmaceutical invention, should deserve &#8230; <a href="http://www.tapanray.in/balancing-ipr-with-public-health-interest-brickbats-power-play-and-bouquets/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/balancing-ipr-with-public-health-interest-brickbats-power-play-and-bouquets/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Government of India accepts the Mashelkar Committee Report on ‘Incremental Innovation’ &#8211; what does it really mean?</title>
		<link>http://www.tapanray.in/the-government-of-india-accepts-the-mashelkar-committee-report-on-incremental-innovation-what-does-it-really-mean/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-government-of-india-accepts-the-mashelkar-committee-report-on-incremental-innovation-what-does-it-really-mean</link>
		<comments>http://www.tapanray.in/the-government-of-india-accepts-the-mashelkar-committee-report-on-incremental-innovation-what-does-it-really-mean/#comments</comments>
		<pubDate>Thu, 20 Aug 2009 01:00:42 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[accepts]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Mashelkar]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[on]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=803</guid>
		<description><![CDATA[&#8216;The Mashelkar Committee&#8217; re-submitted its report in March 2009, which primarily deals with incremental innovation related to Pharmaceuticals Research.The conclusion of the report on the incremental innovation reads as follows:“It would not be TRIPS compliant to limit granting of patents &#8230; <a href="http://www.tapanray.in/the-government-of-india-accepts-the-mashelkar-committee-report-on-incremental-innovation-what-does-it-really-mean/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-government-of-india-accepts-the-mashelkar-committee-report-on-incremental-innovation-what-does-it-really-mean/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is the revised Mashelkar Committee Report a ‘please all’ report, without taking any chance to &#8216;rock the boat&#8217;?</title>
		<link>http://www.tapanray.in/is-the-revised-mashelkar-committee-report-a-please-all-report-without-taking-any-chance-to-rock-the-boat/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-the-revised-mashelkar-committee-report-a-please-all-report-without-taking-any-chance-to-rock-the-boat</link>
		<comments>http://www.tapanray.in/is-the-revised-mashelkar-committee-report-a-please-all-report-without-taking-any-chance-to-rock-the-boat/#comments</comments>
		<pubDate>Mon, 15 Jun 2009 01:00:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[All]]></category>
		<category><![CDATA[any]]></category>
		<category><![CDATA[boat]]></category>
		<category><![CDATA[chance]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[incremental innovation]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Mashelkar]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[please]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Revised]]></category>
		<category><![CDATA[rock]]></category>
		<category><![CDATA[Taking]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[without]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=860</guid>
		<description><![CDATA[After repeated request and persuasion by the Government of India (GoI) in general and the Department of Industrial Policy and Promotion (DIPP) in particular ‘The Mashelkar Committee’re-submitted its reports to the GoI under the following terms of references: Terms of &#8230; <a href="http://www.tapanray.in/is-the-revised-mashelkar-committee-report-a-please-all-report-without-taking-any-chance-to-rock-the-boat/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-the-revised-mashelkar-committee-report-a-please-all-report-without-taking-any-chance-to-rock-the-boat/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Revised Mashelkar Committee Report recommends inclusion of ‘incremental innovation’ under patentability criteria.</title>
		<link>http://www.tapanray.in/revised-mashelkar-committee-report-recommends-inclusion-of-incremental-innovation-under-patentability-criteria/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=revised-mashelkar-committee-report-recommends-inclusion-of-incremental-innovation-under-patentability-criteria</link>
		<comments>http://www.tapanray.in/revised-mashelkar-committee-report-recommends-inclusion-of-incremental-innovation-under-patentability-criteria/#comments</comments>
		<pubDate>Sun, 26 Apr 2009 09:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[compliant]]></category>
		<category><![CDATA[criteria]]></category>
		<category><![CDATA[inclusion]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Mashelkar]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patentability]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recommends]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Revised]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[under]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=906</guid>
		<description><![CDATA[In 2006, the Government of India appointed a Technical Expert Group (TEG) chaired by the eminent scientist and the then Director General of the Council of Scientific and Industrial Research (CSIR) Dr. R.A. Mashelkar, with the following terms of reference:1. &#8230; <a href="http://www.tapanray.in/revised-mashelkar-committee-report-recommends-inclusion-of-incremental-innovation-under-patentability-criteria/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/revised-mashelkar-committee-report-recommends-inclusion-of-incremental-innovation-under-patentability-criteria/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
